bluuebunny/crossref_metadata_2025_split huggingface dataset:
Supramodal Representation of the Sense of Body Ownership in the Human Parieto-Premotor and Extrastriate Cortices
Authors: Sonobe Yusuke , Yamagata Toyoki , Yang Huixiang , Haruki Yusuke , Ogawa Kenji 
Published: January 2023

AbstractThe sense of body ownership, defined as the sensation that one’s body belongs to oneself, is a fundamental component of bodily self-consciousness. Several studies have shown the importance of multisensory integration for the emergence of the sense of body ownership, together with the involvement of the parieto-premotor and extrastriate cortices in bodily awareness. However, whether the sense of body ownership elicited by different sources of signal, especially visuotactile and visuomotor inputs, is represented by common neural patterns remains to be elucidated. We used functional magnetic resonance imaging (fMRI) to investigate the existence of neural correlates of the sense of body ownership independent of the sensory modalities. Participants received tactile stimulation or executed finger movements while given synchronous and asynchronous visual feedback of their hand. We used multivoxel patterns analysis (MVPA) to decode the synchronous and asynchronous conditions with cross-classification between two modalities: the classifier was first trained in the visuotactile sessions and then tested in the visuomotor sessions, and vice versa. Regions of interest (ROIs)-based and searchlight analyses revealed significant above-chance cross-classification accuracies in the bilateral intraparietal sulcus (IPS), the bilateral ventral premotor cortex (PMv), and the left extrastriate body area (EBA). Moreover, we observed a significant positive correlation between the cross-classification accuracy in the left PMv and the difference in subjective ratings of the sense of body ownership between the synchronous and asynchronous conditions. Our findings revealed the neural representations of the sense of body ownership in the IPS, PMv, and EBA that is invariant to the sensory modalities.
Polygonatum polysaccharide attenuates inflammation through inhibiting NLRP3 inflammasome in diabetic cardiomyopathy rats
Authors: Zhao Chun-chun , Zhang Meng , Peng Jian-fei , Ma Yao-yao , Zhao Xiao-ni , Wen Zhong-yu , Wang Shu-shu , Shen An-lu , Shi Hui 
Published: January 2023

Polygonatum polysaccharide (PP) has good myocardial protection. This study aims to find whether PP can relieve inflammation and play a protective role in diabetic cardiomyopathy (DCM). Intraperitoneal injection of streptozotocin was used to induce DCM in rats, which were then separated into four groups: model group, PP-200 group (200 mg/kg PP), PP-400 group (400 mg/kg PP), and Met group (120 mg/kg metformin). Both control (NC) and model groups of rats were administered normal saline. According to the kit instructions mentioned on the kit, the levels of blood glucose, glycosylated hemoglobin, insulin (INS), and myocardial enzymes (creatinine kinase, B-type natriuretic peptide, and cardiac troponin I) were measured after 8 weeks. Cardiac function was detected by echocardiography. Hematoxylin and eosin (HE) and Masson staining were used to observe pathological changes. Myocardial RNA and protein levels of NLR family pyrin domain containing 3 (NLRP3), caspase-1, and Gasdermin D (GSDMD) were quantified through reverse transcription-polymerase chain reaction and Western blotting analysis. The in vivo findings showed that PP could reduce blood glucose, glycosylated hemoglobin, and INS levels, enhance heart functioning, restore histological alterations and myocardial enzymes, and relieve myocardial fibrosis. Furthermore, PP suppressed the expressions of NLRP3, caspase-1, and GSDMD. PP could reduce inflammation in DCM rats by suppressing NLRP3 inflammasome.
Detection rate and characteristics of heart failure, depending on the diagnostic criteria in COVID-19 survivors one year after hospitalization
Authors: Mareev Yu. V. , Lukyanov M. M. , Martsevich S. Yu. , Pulin A. A. , Kutishenko N. P. , Andreenko E. Yu. , Voronina V. P. , Dindikova V. A. , Dmitrieva N. A. , Makoveeva A. N. , Lerman O. V. , Okshina E. Yu. , Smirnov A. A. , Kudryavtseva M. M. , Belova E. N. , Klyashtorny V. G. , Kudryashov E. V. , Karpov O. E. , Drapkina O. M. 
Published: January 2023

Aim. To estimate the detection rate of heart failure (HF), using various diagnosis criteria, among patients aftr 12 months after hospital treatment for coronavirus disease 2019 (COVID-19).Material and methods. The study included 185 patients from the TARGET-VIP registry who came for a visit 12 months after hospitalization for COVID-19. To identify HF with reduced (HFrEF) and mildly reduced (HFmrEF) ejection fraction (EF), the European Society of Cardiology (ESC) criteria (2016 and 2021) were used. To identify HF with preserved EF (HFpEF), we used the ESC criteria (2016 and 2021), as well as the 2018 Russian guidelines and H2FPEF score.Results. In the analyzed group, there were no patients with EF <40%, while one patient had EF of 48% and 184 patients — ≥50%. The patient with EF of 48% was not diagnosed with HF due to the absence of HF signs and symptoms. The presence of HFpEF was confirmed in 31,4% of patients according to 2018 Russian criteria and 2021 ESC criteria (first version of the diagnosis), in 12,5% according to the 2016 ESC criteria, 11% according to ESC 2021 criteria (second version of the diagnosis) and in 2,2% on the H2FPEF score. The proportion of HF diagnosed for the first time according to the 2016 ESC criteria was 78% of the total number of HF cases.Conclusion. Among the examined patients 12 months after hospital treatment for COVID-19, there were no cases of HFrEF and HFmrEF. The proportion of HFpEF cases, depending on the diagnostic criteria used, varied significantly from 2,2 to 31,4%. The previously established diagnosis of HF was confirmed in 83% of cases at a visit 12 months after discharge from the hospital. Using the 2016 ESC criteria and the corresponding 2020 Russian Society of Cardiology guidelines, the proportion of newly diagnosed HF was 78% of all patients.
Predictors of thrombosis of left atrium and its appendage before catheter ablation or cardioversion in patients with non-valvular atrial fibrillation or atrial flutter
Authors: Zaigraev I. A. , Yavelov I. S. , Drapkina O. M. , Bazaeva E. V. 
Published: January 2023

Aim. To determine the incidence of left atrial (LA) and/or LA appendage (LAA) thrombosis in patients with non-valvular atrial fibrillation (AF) (NAF) or atrial flutter (AFL) on transesophageal echocardiography (TEE) before elective catheter ablation (CA) or cardioversion (CV) and characterize the predictors of LA/LAA thrombosis among the indicators available in the routine practice of cardiologists and general practitioners.Material and methods. In this retrospective, single-center, casecontrol study, the medical records of 1994 patients with NAF or AFL for the period 2014-2019, who underwent TEE before CA or elective CV, were analyzed. A thrombus in the LA/LAA was detected in 33 (1,6%) of them. For the comparison group, 167 patients were randomly selected without LA/LAA thrombosis. Demographic, anamnestic and clinical parameters, transthoracic echocardiography data, and laboratory results were analyzed as potential predictors of LA/LAA thrombosis.Results. Patients with LA/LAA thrombosis were older (mean age, 64,8±1,6 vs 59,4±10,8 (p=0,01), more often had persistent or longstanding persistent AF, hypertension, heart failure, enlarged LA, lower left ventricular ejection fraction (LVEF) and estimated glomerular filtration rate, as well as more severe symptoms according to the modified European Heart Rhythm Association (EHRA) score and a higher CHA2DS2-VASc score (median, 4,0 vs 2,0; p=0,0001). Oral anticoagulants were taken by 88% of patients; there were no significant differences in the presence and composition of anticoagulant therapy between the groups. Functional class (FC) according to the modified EHRA score (odds ratio (OR), 5,4; 95% confidence interval (CI): 1,9814,96; p=0,001) and LVEF were independent predictors of LA/LAA thrombosis (OR, 0,87; 95% CI: 0,80-0,95; p=0,002). For EHRA class 3-4, the OR was 5,1; 95% CI: 2,3-11,4 (p<0,0001), for LVEF <48% — 7,4; 95% CI: 1,2-46,7 (p=0,03). For EHRA class 3-4, the sensitivity for LA/LAA thrombosis was 93,7%, specificity — 71,9%, positive predictive value — 50,0%, negative predictive value — 87,6%; for LVEF <48% — 66,7, 32,3, 31,9 and 91,6%, respectively.Conclusion. In the studied group of patients with NAF or AFL, without severe structural heart disease and severe concomitant diseases, most of whom received oral anticoagulants, LA/LAA thrombosis at TEE before elective CA or CV was detected in 1,6% of cases. Among the indicators available in routine medical practice, the severity of arrhythmia symptoms, assessed by the modified EHRA score, and lower LVEF were independent predictors of LA/LAA thrombosis.
Application of the program for artificial intelligence analytics of paper text and segmentation by specified parameters in clinical practice
Authors: Komkov A. A. , Mazaev V. P. , Ryazanova S. V. , Kobak A. A. , Bazaeva E. V. , Samochatov D. N. , Koshkina E. V. , Bushueva Е. V. , Drapkina O. M. 
Published: January 2023

The development of novel technologies using elements of artificial intelligence (AI) in medicine is addressed to practical clinical implementation and provision of key issues, including improvement in the use of routine clinical data, aimed at practical relevance, standardization, confidentiality and patient safety.Aim. To evaluate the effectiveness of the RuPatient electronic heart record (EHR) system in real clinical practice for extracting and structuring medical data.Material and methods. Extraction and recognition of data using EHR from various following sources: outpatient records, statements, routine medical reports, epicrisis and other structured and unstructured medical information based on the developed technology of intelligent text analytics, optical character recognition, for specified words and phrases, and the use of machine learning elements. A particular criterion for evaluating the effectiveness of EHR is the time spent on filling out electronic medical records compared to real clinical practice.Results. The time of entering and processing information by the recognition system of medical documentation included in the RuPatient EHR was shorter than in standard practice (20,3±1,4 minutes, 25,1±1,5 minutes, respectively, p<0,001), the average time of recognition of documents was 30±4,3 seconds. During the ROC analysis, we determined that the threshold value that allows high accuracy to recognize images of discharge epicrisis using the RuPatient system was 83,5% with an area under the curve (AUC) value of 0,76.Conclusions. The developed RuPatient EHR has a medical documentation recognition module for creating structured data based on AI technology elements and can be used in creating an electronic medical history and accumulation of structured data for the implementation of tasks for the practical and scientific use of big data and AI projects in medicine. When using the RuPatient system, the burden on medical staff during document management can be reduced and access to primary medical information simplified.
Influence of catheter-based renal denervation on carbohydrate metabolism in patients with diabetes and hypertension
Authors: Feshchenko D. A. , Rudenko B. A. , Shukurov F. B. , Vasiliev D. K. , Mamedov M. N. , Drapkina O. M. 
Published: January 2023

Aim. To study the effect of catheter-based sympathetic renal denervation (RDN) by radiofrequency ablation on glucose metabolism in patients with type 2 diabetes and uncontrolled hypertension.Material and methods. Sixty patients were randomly assigned in a 1:1 ratio to the RDN group and the control group. Radiofrequency ablation was performed through the femoral access using a Symplicity Spyral™ renal denervation system (Medtronic, USA).Results. The technical success was 100%. There were no any complications. During the follow-up period, patients in the RDN group showed a significant decrease in the average level of glycated hemoglobin — from 7,9 (6,83-8,35) to 6,85 (6,12-7,10)% (p<0,001) and basal glycemia — from 9,5 (7,17-10,28) to 7,55 (6,43-8,95) mmol/l (p<0,001) with no significant changes in the control group. Changes in glucose levels and the degree of insulin resistance correlated with a decrease in office systolic blood pressure (r=0,36, p=0,005). After 6-month follow-up period in the RDN group, along with a significant decrease in the HOMA-IR by 1,92 (p<0,001), the average high-density lipoprotein cholesterol level also significantly increased by 0,17 mmol/l (p<0,001), and mean triglyceride level decreased by -0,55 mmol/l (p<0,001).Conclusion. The study results confirm the hypothesis of pleiotropic effects of RDN in patients with comorbid pathology associated with central sympathetic nervous system hyperactivity (diabetes, hypertension, dyslipidemia).
RBM20 nucleotide sequence variant in a family with a dilated phenotype of left ventricular non-compaction
Authors: Kulikova O. V. , Myasnikov R. P. , Meshkov A. N. , Mershina E. A. , Kiseleva A. V. , Sotnikova E. A. , Kudryavtseva M. M. , Kharlap M. S. , Divashuk M. G. , Zharikova A. A. , Angarsky R. K. , Koretsky S. N. , Filatova D. А. , Sinitsyn V. E. , Drapkina O. M. 
Published: January 2023

Aim. To demonstrate two generations of a family with a progressive course of left ventricular non-compaction (LVNC) and the presence of a RBM20 gene variant.Material and methods. Based on the multicenter registry of patients with LVNC, a family with LVNC with a dilated phenotype was selected at the National Medical Research Center for Therapy and Preventive Medicine. Next generation sequencing was performed on a Nextseq 550 systen (Illumina, USA). For clinical interpretation, nucleotide sequence variants in the genes associated with LVNC development were selected according to the available literature data, with frequencies <0,5% in the gnomAD database. The identified variants were verified using Sanger sequencing on an Applied Biosystem 3500 Genetic Analyzer (Thermo Fisher Scientific, USA).Results. The article presents the results of clinical, paraclinical and molecular genetic studies of two generations of a family diagnosed with LVNC with a dilated phenotype and the progression of isolated LVNC to a dilated type. As a result of a molecular genetic study, all family members with the LVNC were found to have a likely pathogenic variant in the RBM20 NP_001127835.2:p.Pro638Leu (rs267607003) gene. RBM20 is a key splicing regulator that controls the processing of several important transcripts predominantly expressed in striated muscle, especially cardiac tissue. RBM20 gene variants can lead to disruption of splicing at several points and, as a result, to cardiomyopathy progression. Most known pathogenic RBM20 variants are associated with dilated cardiomyopathy; however, a number of studies have found RBM20 gene variants in patients with LVNC. The segregation of nucleotide sequence variant with symptoms in two generations testifies in favor of the association of the detected variant with LVNC development.Conclusion. Currently, the boundaries of the cardiomyopathy genetics are expanding. Pathogenic and likely pathogenic RBM20 gene variants are associated primarily with a dilated phenotype and a high risk of sudden cardiac death. The article presents the results of a survey of two generations of a family with LVNC and progressive myocardial remodeling.
Reactogenicity of various COVID-19 vaccination regimens
Authors: Drapkina O. M. , Berns S. A. , Gorshkov A. Yu. , Ryzhakova L. N. , Zhdanova O. V. , Chaschin M. G. , Litinskaya O. A. 
Published: January 2023

During the spread of an increasing number of new variants of Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2), it is extremely important not only to assess the immunogenicity and efficacy, butalso the safety of various combinations of vaccines. Excessive immune response and associated signs and symptoms may occur with varying frequency as expected from the use of vaccines.Aim. To compare the reactogenicity of various (heterologous and homologous) vaccination regimens in a prospective observational study.Material and methods. In individuals aged ≥18 years, in the absence of contraindications to vaccination, two types of vaccines were used at primary vaccination and revaccination: Gam-COVID-Vac and CoviVac: group I (n=97) — Gam-COVID-Vac at each stage of primary and booster vaccination ; group II (n=7) — Gam-COVID-Vck at each stage of primary vaccination, CoviVac at each stage of revaccination; group III (n=42) — CoviVac at each stage of primary vaccination, Gam-COVID-Vac at each stage of revaccination; group IV (n=38) — CoviVac at each stage of primary and secondary vaccination. In all participants, the dynamics of IgG to SARS-CoV-2 spike glycoprotein receptor-binding domain and T-cell immunity to SARS-CoV-2 were determined over time. To control the plasma hemostasis, the method of dynamic thrombophotometry was used. Local and systemic adverse events were assessed.Results. The number of vaccinated individuals with a rise in body temperature above 370 C after the 1st stage of revaccination was significantly (p<0,05) more in group I (37,5%) and group II (57,1%) compared with vaccinated persons of IV group. At the same time, after the 2nd stage of revaccination, in general, a smaller percentage of vaccinated persons with hyperthermia was noted. In group I, a higher percentage of persons (22,9%) complaining of the appearance of weakness after stage I of revaccination was noted compared to vaccinated persons of group IV — 5,2%. An increase in the fibrin clot growth rate was noted in group III at the stage of revaccination.Conclusion. The use of various revaccination schemes (homologous and heterologous) was not associated with the development of serious adverse events. The resulting local and systemic reactions were shortlived and did not require hospitalization. More pronounced systemic reactions were noted in the form of a short-term fever and weakness when using the Gam-COVID-Vac. No cases of arterial or venous thrombosis were registered during the follow-up period.
Comparative assessment of the immunogenicity of various revaccination regimens against the SARS-CoV-2
Authors: Drapkina O. M. , Berns S. A. , Gorshkov A. Yu. , Ryzhakova L. N. , Zhdanova O. V. , Chaschin M. G. , Litinskaya O. A. , Savicheva A. A. , Pokrovskaya M. S. 
Published: January 2023

Along with efficacy and safety, it is extremely important to study the severity of humoral and cellular immunity during not only vaccination, but also revaccination against the Severe Acute Respiratory Syndromerelated CoronaVirus 2 (SARS-CoV-2).Aim. To compare the immunogenicity (humoral and cellular immunity) of various (heterologous and homologous) revaccination regimens against coronavirus disease 2019 (COVID-19) in a prospective observational study.Material and methods. In individuals aged ≥18 years, in the absence of contraindications to vaccination, two following types of vaccines were used for primary vaccination and revaccination: Gam-COVIDVac and CoviVac. Group I patients received Gam-COVID-Vac at each stage of primary and secondary vaccination; patients of group II — Gam-COVID-Vac at each stage of primary vaccination, CoviVac at each stage of re-vaccination; patients of group III — CoviVac at each stage of primary vaccination and Gam-COVID-Vac at each stage of revaccination; patients of group IV — CoviVac at each stage of primary and secondary vaccination. All participants (at each stage of vaccination, revaccination and 12 months after the primary vaccination) were determined the level of IgG to the receptor-binding domain of SARS-CoV-2 spike (S) protein and T-cell immunity to SARSCoV-2.Results. The maximum level of IgG at the second stage of revaccination was observed in groups I and III. In addition, in groups I, III and IV, a significant (p<0,0001) increase in IgG level by the second stage of revaccination was noted, the most pronounced in group III. In addition, there was a significantly (p<0,05) higher level of IgG at I and II stages of revaccination (Visit 3 and 4) among those vaccinated with Gam-COVID-Vac — 520 and 540 BAU/ml, respectively, compared with group IV vaccinated with CoviVac — 467 and 478 BAU/ml, respectively. The maximum and significant increase in active T-cells by the second stage of revaccination (Visit 4) was noted in groups I (p<0,0001) and III (p<0,0022) of vaccinated individuals, where it amounted to 11 and 12, respectively, which allows to consider the result positive (>8). At the same time, the level of active T cells responding to SARS-CoV-2 nucleocapsid Ag stimulation by Visit 4 (stage II of revaccination) was noted in groups II (14,5) and IV (12).Conclusion. The use of the Gam-COVID-Vac vaccine as a booster dose in both homologous and heterologous vaccination regimens against the SARS-CoV-2 virus is most effective for stimulation and humoral and T-cell post-vaccination response.
Simultaneous Seismic Phase Picking and Polarity Determination with an Attention-Based Neural Network
Authors: Zhang Ji , Li Zefeng , Zhang Jie 
Published: January 2023

AbstractEarthquake focal mechanisms present information on fault plane and stress direction, which is crucial for understanding tectonics and seismicity. Source focal mechanisms of small earthquakes are often difficult to determine from waveform modeling but feasible to infer from initial polarities. Here, we employ a state-of-the-art neural network infused with an attention mechanism to simultaneously pick arrivals and determine the first-motion polarity. The model is trained and tested with data from southern California. Compared with polarity inference with manual picks in the catalog, predicted polarity inference can help obtain more focal mechanism solutions in southern California. We test this model with data from different regions and observe high generalizability. The predicted arrival and polarity data are consistent with the labeled arrival and polarity data in Japan. The average-picking error is 0.04 s, and the accuracy of polarity classification is 99%. We infer the focal mechanisms from the predicted polarity in Oklahoma. The derived focal mechanisms are consistent with referencing focal mechanisms. This method allows routinely obtaining arrival and polarity data, and deriving focal mechanism solutions for events.
A comparative review of the activity of enzymes of the cytochrome P450 system in humans and laboratory animals. Prognostic value of preclinical models in vivo
Authors: Miroshnikov M. V. , Sultanova K. T. , Makarova M. N. , Makarov V. G. 
Published: January 2023

Cytochrome P450 enzymes play a key role in drug biotransformation. The expression and activity of each CYP450 is influenced by a unique combination of biochemical factors, species and genetic differences, age, sex, nutrition and etc.Cytochromes P450 are a family of heme-containing proteins involved in the metabolism of xenobiotics, drugs, and endogenous compounds. Drugs could act as inducers or inhibitors of cytochrome P450 enzymes. Understanding the mechanisms of inhibition or induction of enzymes is extremely important in preclinical studies and prescribing complex therapy. One of the main challenges in the development of therapeutic agents is to determine which animal species reflects the human ability to metabolize certain drugs. The study of CYPs and their interaction with drugs is an urgent problem in preclinical studies. Thus, an adequate and maximally similar experimental preclinical models are necessary to study the pharmacokinetic and pharmacodynamic properties of promising chemicals and their effect on certain cytochrome P450 enzymes.This review compares the main subfamilies and their enzymes of the cytochrome system of humans and laboratory animals involved in drug metabolism. The problems of choosing biological models in vivo in preclinical studies in the study of medicinal substances are considered. The predictive value of in vivo models of preclinical studies was analyzed from the point of view of the cytochrome P450 system in humans and laboratory animals.